George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Share News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: REIT's Rise On Carney Message, Sector Activity

Wed, 25th Jun 2014 11:44

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.
-------
FTSE 100 - WINNERS
-------
Hammerson, up 1.1%, British Land Company, up 0.7%, and Land Securities Group, up 0.4%. The interest-rate-sensitive real estate investment trusts are among the leading gainers in the blue-chip index after Bank of England governor Mark Carney watered down his message from the previous week about an early interest rate rise. Speaking before the UK government's Treasury Select Committee on Tuesday, the BoE chief insisted there is still a lot of slack in the UK labour market to be used up, a much more dovish tone than he had just days earlier at his Mansion House speech. A significant deal in the industry also has provided a boost to the sector. Land Securities has bought a 30% stake in the Bluewater shopping centre in Kent from Australian property business Lease Group, in a deal worth GBP656 million in cash. Press reports had suggested that Hammerson and British Land were looking to buy the stake in the shopping centre. While they missed out, both companies' share prices jumped on the news as there had been concerns over the viability of the deal for both of them, particularly Hammerson, which would likely have had to carry out a share placing to finance the transaction, analysts say. In fact, Jefferies' analyst Rob Duncan believes that Hammerson is experiencing a "relief-rally" after it missed out on the deal.

Shire, up 0.6%. The pharmaceutical company said that it has received the backing of a US court over claims against patents on its Vyvanse hyperactivity disorder drug. Shire said that the ruling prevents five pharmaceutical manufacturers which have filed applications to launch generic versions of Vyvanse from doing so unless they successfully appeal the ruling or until the patents expire in 2023.
-------
FTSE 100 - LOSERS
-------
Bunzl, down 2.9%. The company said it expects to report 6% revenue growth at constant exchange rates for the first half of 2014, due to underlying revenue growth of about 2% and an uplift from acquisitions, but it reiterated its reported results will be hit by foreign exchange fluctuations. In addition, Bunzl said that it has made two new acquisitions, as it looks to give a boost to its safety business in the Netherlands and expand its cleaning and hygiene supplies business in Brazil.

Experian, down 2.6%. The credit checking and information company is one of the biggest fallers in the blue-chip index after going ex-dividend, meaning new buyers no longer qualify for the latest dividend payout.
-------
FTSE 250 - WINNERS
-------
Northgate, up 1.1%. The vehicle rental company said it swung to profit in its last financial year, as it reaped the cost benefits of a refinancing. It posted pretax profit of GBP51.2 million for the year to end-April, compared with a GBP11.4 million loss a year earlier, as it benefited from a GBP24.5 million reduction in interest payments following the group's refinancing in April 2013. In the previous year, the company's results were affected by GBP53.9 million in finance costs including the cost of exiting the group's legacy debt and hedging. Revenue, which incorporate vehicle and hire sales, dropped slightly to GBP571.5 million, from GBP609.9 million.
-------
FTSE 250 - LOSERS
-------
Tate & Lyle, down 4.6%, AVEVA Group, down 4.3%, Electrocomponents, down 2.6%, TR Property Investment Trust, down 1.9%, MITIE Group, down 1.4%, and Paypoint, down 1.2%. All six have gone ex-dividend Wednesday.

Premier Oil, down 1.7%. The oil and gas producer said it has appointed Tony Durrant as chief executive officer with immediate effect. Durrant has been with the company since 2005, serving as finance director. Before this he worked at Lehman Brothers, latterly as managing director and head of the European natural resources group.
-------
AIM ALL-SHARE - WINNERS
-------
Akers Biosciences, up 17%. The company has inked a distribution agreement for its PIFA Heparin/PF4 and PIFA PLUSS PF4 test kits with Medline Industries Inc. Under the agreement Medline will begin marketing the tests over its network of hospitals and surgery centres across the US. Its sales representatives will market to multiple departments within each hospital, which Akers believes will increase the market penetration of the products. The tests check for heparin-induced thrombocytopenia, which may occur if a patient develops an allergy to the blood thinning drug heparin. No financial details of the agreement were disclosed.

Stellar Resources, up 8.4%. The company said its two tonne per hour gold processing plant has now arrived at the Clogau St David's gold mine in North Wales. The company said the plant will now be constructed in modified facilities near the entrance to the Clogau mine, a famous site which once provided gold for the British Royal Family, before commissioning. The new treatment plant will allow the start of small-scale pilot processing of gold ore and also to help assess underground samples. The underground workings of the mine have been rehabilitated over the past few years, and the owners are hoping tests will show that gold can again be mined profitably at the site using new technology.
-------
AIM ALL-SHARE - LOSERS
-------
Synectics, off 25%. The surveillance technology and networked security systems company has seen a quarter of its market value wiped out after it said results for the first half of its current financial year, and for the year as a whole, will be "significantly below market expectations" largely due to contract delays. It said it now expects to report an underlying pretax loss of around GBP2.5 million for the first half of the year, and will therefore not pay an interim dividend. It said the biggest hit to its full-year results for the year to end-November is being caused by the current fighting in Iraq.

Acta SPA, down 17%. The company's shares have tumbled after it cautioned that its revenue for the year may be below current market expectations after the company under-estimated the length of sales cycles in the telecoms market. The company said that, whilst its remains confident it will see strong revenue growth for the year across its business lines, its experience over the last six months has shown that sales cycles in the telecoms sector are longer and more difficult to determine than it had previously estimated.

Byotrol, down 16%. The company's loss narrowed in its last financial year, as revenue rose slightly, it cut administrative expenses and booked a one-off gain associated with the acquisition of Byotrol Consumer Products. However, shares in the company are down sharply as it also said it had raised GBP1.25 million before expenses via a share subscription and placing priced at 3 pence per share. It said it would use the funds raised to invest in sales and marketing resources, expansion, intellectual property development, and working capital. Byotrol's shares are currently quoted at 3.255 pence.

Petrel Resources, down 11%. The oil and gas explorer said its pretax loss widened slightly in 2013 and warned that its assets in Ireland, Ghana and Iraq all face difficulties. The company, which is yet to produce any revenues, said its pretax loss widened to EUR526,783 from EUR469,767 the previous year. The vast majority of its costs were administrative expenses, which increased to EUR528,597 from EUR481,427 during the period. The company said its interest in the Block 6 oil exploration licence in the Anbar province of Iraq has been hit by the ongoing crisis in the country, and in Ghana, it has struggled with a dispute over its rights to an exploration block, known as the Ghana Tano 2A block, in shallow water offshore. Furthermore, the company's flagship projects in the Atlantic Ocean's Porcupine Basin, offshore Ireland, may be hit by changes to the fiscal regime in Ireland, including royalties and higher taxes, which have pushed some investors from the country.
-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute with Pulse Health.

Read more
15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid assay products had offset a stronger showing in its breathalyser unit.

Read more
3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.The AIM-listed firm

Read more
16 Mar 2018 18:11

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from warrants to

Read more
16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable markers. The US Patent and Trademark Office has given a patent for its proprietary cartridge for the optical scanning device used in the company's Brea

Read more
10 Jan 2017 12:06

Akers Biosciences to raise $2m in US placing

(ShareCast News) - Rapid diagnostic test manufacturer Akers Biosciences said it plans to issue $2m of new shares plus warrants over another $1m worth of shares. The AIM- and Nasdaq-listed outfit said funds will be used for working capital as well as to accelerate growth in the US and in internationa

Read more
19 Dec 2016 14:52

Akers Biosciences signs three year deal with US hospital group

(ShareCast News) - Rapid health information technology developer Akers Biosciences announced on Friday it has signed a three-year agreement with the Greater New York Hospital Association to introduce its flagship rapid tests for heparin-induced thrombocytopenia across the association's network of ov

Read more
12 Dec 2016 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Dec 2016 12:13

Akers Agrees Deal For First Check To Sell Cholesterol Test In US

Read more
10 Nov 2016 09:46

Akers Biosciences gains European patent for ketone breath device

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, gains a European patent for its ketone acid breath device. The European Patent Office has issued a patent covering the company's breath ketone detector, a breath device to monitor ketone levels, which follows

Read more
19 Aug 2016 12:18

Akers Biosciences, ChubeWorkx settle lengthy legal dispute

(ShareCast News) - Akers Biosciences has reached a settlement agreement with former distributor ChubeWorkx Guernsey Ltd, allowing it to recover $1.25m in product and cash and end a lengthy legal dispute between the pair. ChubeWorkx would recover what it was owed from a promissory note by taking deli

Read more
18 Aug 2016 07:22

Akers Says Test Results "Highly Successful" For BreathScan OxiChek

Read more
30 Jun 2016 08:56

Akers Says Rapid Chlamydia Test Trial "Highly Successful"

Read more
27 Jun 2016 08:16

Akers Biosciences Signs First Distribution Deal For BreathScan OxiChek

Read more
26 May 2016 16:27

DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.